Leerink Partnrs Has Optimistic Outlook of VRTX Q3 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Analysts at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Wednesday, June 25th. Leerink Partnrs analyst D. Risinger now expects that the pharmaceutical company will earn $4.29 per share for the quarter, up from their prior estimate of $4.28. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter last year, the firm posted $4.76 EPS. The business's revenue for the quarter was up 2.6% compared to the same quarter last year.

A number of other research analysts have also weighed in on VRTX. Bank of America raised their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research note on Monday, March 31st. JPMorgan Chase & Co. raised their price objective on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Leerink Partners restated a "market perform" rating and set a $503.00 price objective (down from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $511.62.

Vertex Pharmaceuticals Stock Down 0.5%

Shares of Vertex Pharmaceuticals stock traded down $2.10 during trading hours on Thursday, reaching $441.30. The company's stock had a trading volume of 3,615,473 shares, compared to its average volume of 1,418,238. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The company has a market capitalization of $113.33 billion, a P/E ratio of -112.58 and a beta of 0.42. The stock's fifty day simple moving average is $454.50 and its two-hundred day simple moving average is $458.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its holdings in Vertex Pharmaceuticals by 75.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock worth $994,000 after acquiring an additional 1,062 shares during the last quarter. Aries Wealth Management purchased a new stake in Vertex Pharmaceuticals in the 1st quarter worth about $293,000. Polar Asset Management Partners Inc. purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth about $22,954,000. Brighton Jones LLC increased its holdings in Vertex Pharmaceuticals by 45.0% in the 1st quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company's stock worth $3,113,000 after acquiring an additional 1,994 shares during the last quarter. Finally, APG Asset Management N.V. increased its holdings in Vertex Pharmaceuticals by 189.7% in the 4th quarter. APG Asset Management N.V. now owns 359,285 shares of the pharmaceutical company's stock worth $139,724,000 after acquiring an additional 235,265 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.